Protein Microarrays for Personalized Medicine

被引:77
|
作者
Yu, Xiaobo [1 ]
Schneiderhan-Marra, Nicole [1 ]
Joos, Thomas O. [1 ]
机构
[1] Univ Tubingen, NMI Nat & Med Sci Inst, D-72770 Reutlingen, Germany
关键词
PATIENT-TAILORED THERAPY; BIOCHIP ARRAY TECHNOLOGY; CELL SIGNALING ANALYSIS; BREAST-CANCER; BIOMARKER DISCOVERY; OVARIAN-CANCER; RHEUMATOID-ARTHRITIS; MULTIPLEX ANALYSIS; SERUM BIOMARKERS; SYSTEMS BIOLOGY;
D O I
10.1373/clinchem.2009.137158
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BACKGROUND: Over the last 10 years, DNA microarrays have achieved a robust analytical performance, enabling their use for analyzing the whole transcriptome or for screening thousands of single - nucleotide polymorphisms in a single experiment. DNA microarrays allow. scientists to correlate gene expression signatures with disease progression, to screen for disease-specific mutations, and to treat patients according to their individual genetic profiles; however, the real key is proteins and their manifold functions. It is necessary to achieve a greater understanding of not only protein function and abundance but also their role in the development of diseases. Protein concentrations have been shown to reflect the physiological and pathologic state of an organ, tissue, or cells far more directly than DNA, and proteins can be profiled effectively with protein microarrays, which require only a small amount of sample material. CONTENT: Protein microarrays have become well-established tools in basic and applied research, and the first products have already entered the in vitro diagnostics market. This review focuses on protein microarray applications for biomarker discovery and validation, disease diagnosis, and use within the area of personalized medicine. SUMMARY: Protein microarrays have proved to be reliable research tools in screening for a multitude of parameters with only a minimal quantity of sample and have enormous potential in applications for diagnostic and personalized medicine. (C) 2009 American Association for Clinical Chemistry
引用
收藏
页码:376 / 387
页数:12
相关论文
共 50 条
  • [31] Personalized Medicine
    Eyerich, Kilian
    Tueting, Thomas
    HAUTARZT, 2019, 70 (01): : 4 - 4
  • [32] PERSONALIZED MEDICINE
    Saxena, Ashok Kumar
    EVERYMANS SCIENCE, 2015, 50 (01): : 4 - 5
  • [33] Reverse-phase protein microarrays: application to biomarker discovery and translational medicine
    VanMeter, Amy
    Signore, Michele
    Pierobon, Mariaelena
    Espina, Virginia
    Liotta, Lance A.
    Petricoin, Emanuel F., III
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2007, 7 (05) : 625 - 633
  • [34] Personalized Medicine: Medicine for the Privileged?
    Helft, Paul R.
    Misra, Satish
    ONCOLOGY-NEW YORK, 2012, 26 (09): : 814 - 819
  • [35] Personalized medicine or precision medicine?
    Faiz, Kashif Waqar
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2020, 140 (01) : 84 - 84
  • [36] Precision medicine or personalized medicine?
    Caplan, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 30 - 30
  • [37] Personalized Medicine in Oncology; a Special Issue of the Journal of Personalized Medicine
    VanderWalde, Ari
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (07):
  • [38] Balancing Personalized Medicine and Personalized Care
    Cornetta, Kenneth
    Brown, Candy Gunther
    ACADEMIC MEDICINE, 2013, 88 (03) : 309 - 313
  • [39] Open Innovation as the Catalyst in the Personalized Medicine to Personalized Digital Medicine Transition
    Cesario, Alfredo
    D'Oria, Marika
    Simone, Irene
    Patarnello, Stefano
    Valentini, Vincenzo
    Scambia, Giovanni
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (09):
  • [40] Coriell Personalized Medicine Collaborative®: a prospective study of the utility of personalized medicine
    Keller, Margaret A.
    Gordon, Erynn S.
    Stack, Catharine B.
    Gharani, Neda
    Sill, Courtney J.
    Schmidlen, Tara J.
    Mintzer, Joseph
    Pallies, John
    Gerry, Norman P.
    Christman, Michael F.
    PERSONALIZED MEDICINE, 2010, 7 (03) : 301 - 317